Elanco Animal Health has delivered a sharp 154.5% return over the past three years, which naturally puts the focus on whether the current US$22.55 share price lines up with the cash the business can generate. With attention now on products like Zenrelia and the broader pet health opportunity, the key issue is whether those cash flows are strong and durable enough to support where the stock trades today.
- A 154.5% gain over three years places real weight on the question of whether Elanco Animal Health's current valuation is grounded in its cash flow potential rather than just a strong share price run.
- Zenrelia treating more than 2,000,000 dogs and gaining high prescribing loyalty may support expectations for steadier future cash inflows from Elanco Animal Health's dermatology franchise.
- What if you looked at Elanco Animal Health through its sales instead? See what Elanco Animal Health's 2.2x P/S says about the price.
The issue now is whether Elanco Animal Health's current price is adequately backed by its projected cash flows when viewed through a Discounted Cash Flow (DCF) lens.
If you want more ideas built on the same question of whether price is backed by cash generation, start a watchlist from 33 high quality undervalued stocks.
Does Elanco Animal Health Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at the cash Elanco Animal Health can return to shareholders over time and discounts it back to today. Latest twelve month free cash flow sits around $397.9 million, and analyst projections point to higher free cash generation over the coming decade, which feeds into a 2 Stage Free Cash Flow to Equity model.
Those cash flow estimates, combined with the discounting used in the DCF, result in an estimated intrinsic worth that is substantially above the current $22.55 share price. News that Zenrelia has treated more than 2,000,000 dogs with very high prescribing loyalty gives one concrete example of why some investors may view those projected cash flows as more durable, even if the market price has not fully reflected that view yet. Find out what Elanco Animal Health could be worth using our Discounted Cash Flow (DCF) estimate.
The Elanco Animal Health Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Elanco Animal Health pick up where the valuation question leaves off. They spell out which expectations on growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today's price on the Community page. Each one turns Elanco Animal Health's fair value into a specific thesis about the business that can be tracked over time rather than a one-off snapshot.
One of the top community narratives on Elanco Animal Health: 34% undervalued
"The completion of Elanco Animal Health’s US$120 million expansion in Elwood, Kansas that quadruples monoclonal antibody capacity gives the company room to scale Befrena, Trutect and additional biologics…"
Discover why this Narrative puts Elanco Animal Health at 34% undervalued.
One more piece to weigh before acting on Elanco Animal Health's valuation
Before you lean too heavily on the numbers around Elanco Animal Health, it is worth checking who is steering the business and how their rewards line up with your interests. See who runs Elanco Animal Health and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com